NAD+ Oral Supplement Pilot Intervention in Adult Females

Last updated: March 10, 2026
Sponsor: University of Rhode Island
Overall Status: Completed

Phase

N/A

Condition

Inflammation

Multiple Sclerosis

Neurologic Disorders

Treatment

Nicotinamide adenine dinucleotide

Placebo

Treatment

Clinical Study ID

NCT06579209
2087241-4
P20GM103430
  • Ages 40-80
  • Female
  • Accepts Healthy Volunteers

Study Summary

The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are:

Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ.

Participants will:

Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Identify as Female

  • Have a BMI of 18.5 or above

  • Must be able to swallow tablets

Exclusion

Exclusion Criteria:

  • Those who are pregnant, breastfeeding, or taking hormone medication

Study Design

Total Participants: 53
Treatment Group(s): 3
Primary Treatment: Nicotinamide adenine dinucleotide
Phase:
Study Start date:
December 01, 2024
Estimated Completion Date:
February 20, 2026

Connect with a study center

  • University of Rhode Island

    Kingston, Rhode Island 02881
    United States

    Site Not Available

  • Independence Square, University of Rhode Island

    Pawtucket, Rhode Island 02860
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.